Objective: This study aimed to evaluate oncologic outcomes of women with stage IB1 cervical cancer treated with uterine-preserving surgery (UPS) (defined as conization or trachelectomy) versus non-UPS (defined as hysterectomy of any type). Methods: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify women younger than 45 years diagnosed with stage IB1 cervical cancer from 1998 to 2012. Only those who underwent lymph node (LN) assessment were included. Outcomes of UPS versus non-UPS were analyzed. Results: Among 2717 patients, 125 were treated with UPS and 2592 were treated with non-UPS. Those in the UPS group were younger (median age 33 vs 37 years, P G 0.001), less commonly had tumor size greater than 2 cm (27% vs 45%, P G 0.001), and less commonly received adjuvant radiation therapy (18% vs 29%, P = 0.006). There was no difference in distribution of tumor grade, histology, or rate of LN positivity. Median follow-up was 79 months (range, 0Y179). There was no difference in 5-year disease-specific survival (DSS) between the UPS versus non-UPS groups (93% vs 94%, respectively, P = 0.755). When stratified by tumor size, DSS for UPS versus non-UPS was as follows: tumors 2 cm or less, 96.8% versus 96.3% (P = 0.683); tumors greater than 2 cm, 82.4% versus 90.4% (P = 0.112). Factors independently associated with worsened survival included adenosquamous histology (hazard ratio [HR] 2.29, 95% confidence interval [CI]1.51Y3.47), G3 disease (HR 2.44, 95% CI 1.01Y5.89), tumor size greater than 2 cm (HR 1.93, 95% CI 1.36Y2.75) and LN positivity (HR 2.29, 95% CI 1.64Y3.22). The UPS was not associated with a higher risk of death. Conclusions: The UPS does not seem to compromise oncologic outcomes in a select group of young women with stage IB1 cervical cancer, especially in the setting of tumors 2 cm or less. Further studies are needed to clarify the role of UPS in tumors greater than 2 cm.
Standard therapy for International Federation of Gynecology and Obstetrics (FIGO) Stage IB1 cervical cancer is radical hysterectomy with bilateral pelvic lymphadenectomy, resulting in loss of fertility. However, many women now delay childbearing. Therefore, uterine preservation is of great importance to younger women (G45 years) diagnosed with cervical cancer.
Radical vaginal trachelectomy, as a means of uterine preservation, was first introduced by Dargent et al 2 in 1994 . A variety of additional uterine-preserving surgeries (UPS) have been proposed since that time: abdominal radical trachelectomy (by laparotomy or minimally invasive approach), simple trachelectomy, and cervical conization alone. 2Y5 The goal of these procedures is to preserve fertility without compromising oncologic outcomes. More than 2 decades of accumulated data from small retrospective studies have shown that, in properly selected patients, a conservative surgical approach with radical trachelectomy is both feasible and safe. 6, 7 The National Comprehensive Cancer Network (NCCN) guidelines now include radical trachelectomy with either pelvic lymph node (LN) dissection or sentinel lymph node mapping as acceptable options in the management of women with FIGO stage IB1 cervical cancer who wish to maintain reproductive function.
There has been increasing interest in further reducing the morbidities associated with radical trachelectomy by performing simple conization alone. 8, 9 However, there are very limited data regarding the oncologic safety of conization alone because the majority of published reports on fertility preservation have focused on trachelectomy for IB1 disease. Many studies on UPS are based on small sample sizes and short follow-up, making it difficult to draw generalizable conclusions for evidence-based practice. The majority of published studies also combine several FIGO stages for analysis, resulting in limited data pertaining to a single stage of disease. In addition, tumors greater than 2 cm are associated with higher risk of recurrence and worse overall survival (OS), and clinicians are less likely to offer uterine preservation in the setting of these larger tumors. 10Y13 As a result, there are little data concerning the safety of UPS in patients with larger IB1 tumors. Our primary aim was to evaluate long-term oncologic outcomes of younger women with stage IB1 cervical cancer treated with UPS compared with those treated with non-UPS. Our secondary aim was to assess demographic and clinical factors associated with UPS versus non-UPS.
METHODS
Data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database were used. The SEER is a national population-based cancer registry that covers approximately 28% of the US population and comprises several geographically distinct tumor registries. The demographic characteristics of the SEER registries have been previously described.
14 The SEER 18 registries were used for this analysis, which include data from 18 geographic areas located in 13 different states.
We identified women younger than 45, diagnosed with FIGO Stage IB1 squamous cell, adenocarcinoma, or adenosquamous cervical cancer between January 1998 and December 2012, who were treated with primary surgery. Only those who After sequentially excluding those with stage IB2 disease (n = 735), stage IB disease not otherwise specified (NOS; n = 1018), nonsquamous cell/adenocarcinoma/adenosquamous histology (n = 617), undifferentiated grade (n = 47), and those who did not undergo regional lymph node assessment (n = 284), we arrived at our final cohort of 2717 patients. Demographic and clinicopathologic data, including age at diagnosis, race (white, black, Hispanic, other), marital status (single, married/domestic partner, divorced/widowed/ separated, unknown), geographic area of residence at the time of diagnosis, year of diagnosis, histologic subtype, grade (G1, G2, G3, unknown), tumor size, primary surgical treatment, performance of lymphadenectomy, LN status, and adjuvant radiation therapy (RT) (none, external beam, brachytherapy, both) were examined. The SEER registry staff is instructed to code the most extensive surgery if patients have had multiple surgical procedures of the primary site. Thus, patients who underwent only a trachelectomy were coded as having had a trachelectomy, whereas patients who underwent a trachelectomy followed by a completion hysterectomy were coded as having had a hysterectomy. Year of diagnosis was stratified by 4-year intervals (1998Y2002, 2003Y2007, 2008Y2012) and geographic area of residence was categorized as central (Detroit, Iowa, Kentucky, Louisiana, Utah), eastern (Atlanta, Connecticut, New Jersey, greater Georgia, rural Georgia), or western (Alaska, California, Hawaii, Los Angeles, New Mexico, Seattle, San Francisco/Oakland, San Jose).
Analysis was based on whether patients underwent UPS or non-UPS as their primary treatment. The UPS was defined as conization alone or trachelectomy; non-UPS was defined as hysterectomy of any type (including simple hysterectomy, modified radical or radical hysterectomy, and hysterectomy not otherwise specified [NOS]). Trachelectomy was not further specified as being simple or radical in the SEER database. Characteristics and outcomes of patients treated with UPS were compared with those treated with non-UPS.
Statistical Analysis
Categorical variables were compared using the W 2 test. Median values for continuous variables were compared using the Mann-Whitney U test. Predictors of UPS were analyzed using univariate and multivariable logistic regression models. The Kaplan-Meier method was used to estimate disease-specific survival (DSS), and survival distributions were compared using the log-rank test. The DSS was defined as the time from date of diagnosis to date of death due to disease. Patients who were deceased from nonYdisease-related causes, or alive at the time of analysis, were censored. Median follow-up time was calculated using the Kaplan-Meier estimate of potential follow-up. Factors associated with DSS were evaluated using the Cox proportional hazards model. Clinically significant variables and variables with a P value less than 0.2 on univariate analysis were included in a multivariable analysis. All variables were tested for multicollinearity. Calculated P values were 2-tailed, and P values less than 0.05 were considered significant. Statistical analyses were performed using IBM SPSS for Windows, version 24.0 (IBM Corporation, Armonk, NY). Table 1 . Median age overall was 37 years (range, 17Y44). Most patients were either married or in a relationship with a domestic partner (n = 1470, 54%). The most common histology was squamous cell (n = 1804, 66%); 1477 (54%) of tumors were 2 cm or less. Four hundred sixty-six patients (17%) had positive LNs. Seven hundred seventy patients (28%) received adjuvant RT.
RESULTS
Among these 2717 patients, 125 underwent UPS with conization (n = 36) or trachelectomy (n = 89). The remaining 2592 patients underwent non-UPS with either simple hysterectomy (n = 682), modified radical/radical hysterectomy (n = 1764), or hysterectomy NOS (n = 146). Table 2 summarizes the demographic and clinicopathologic characteristics of those treated with UPS versus non-UPS. Patients in the UPS group were younger (median age 33 vs 37 years), were more often diagnosed between 2008 and 2012 (55% vs 36%), more commonly presented with tumor size 2 cm or less (70% vs 54%), and less commonly received adjuvant RT (18% vs 29%). There were no significant differences in race, marital status, SEER region, histology, grade, or LN positivity between the groups.
Factors associated with UPS are shown in Median follow-up for the entire cohort was 79 months (range, 0Y179). The DSS data are summarized in Table 4 . As depicted by the Kaplan-Meier curves (Fig. 1A) , there was no significant difference in 5-year DSS between the 2 groups (92.9% vs 93.7% for UPS and non-UPS, respectively [P = 0.755]). One thousand four hundred seventy-seven women had tumors 2 cm or less; 1197 had tumors greater than 2 cm. Of those with tumors 2 cm or less, 87 underwent UPS (conization n = 19, trachelectomy n = 68) and 1390 underwent non-UPS (simple hysterectomy n = 387, modified radical/radical hysterectomy n = 949, hysterectomy NOS n = 63). Of those with tumors greater than 2 cm, 34 underwent UPS (conization n = 16, trachelectomy n = 18) and 1163 underwent non-UPS (simple hysterectomy n = 285, modified radical/radical hysterectomy n = 797, hysterectomy NOS n = 81). Five-year DSS for those with tumors 2 cm or less was 96.8% for the UPS group versus 96.3% for the non-UPS group (P = 0.683; Fig. 1B ). There was no statistically significant difference in 5-year DSS for patients with tumors greater than 2 cm (DSS 82.4% for the UPS group versus 90.4% for the non-UPS group, P = 0.112; Fig. 1C ). However, when comparing survival between all patients with tumors 2 cm or less to those with tumors greater than 2 cm, regardless of UPS or non-UPS, patients with larger tumors had significantly worse 5-year DSS (tumor G2 cm 96.3% vs tumor 92 cm 90.2%, P G 0.001; Fig. 1D ). Patients with negative LNs had improved 5-year DSS compared with those with positive LNs (95.3% vs 85.5%, P G 0.001), and patients who did not receive adjuvant RT had improved survival compared with those who did receive adjuvant RT (96% vs 87.8%, P G 0.001).
We examined the long-term outcomes of women in whom reproductive function was truly preserved, defined as not requiring adjuvant RT after UPS. We found no significant difference in 5-year DSS between UPS (n = 103) and non-UPS (n = 1844) in patients who did not receive adjuvant RT (DSS was 94.8% for the UPS cohort versus 96.0% for the non-UPS cohort, P = 0.616; Fig. 1E ). Among patients with tumors 2 cm or less who underwent UPS, 90.8% did not receive adjuvant RT. In comparison, 41.2% of patients with tumors greater than 2 cm who underwent UPS received adjuvant RT; thus, only 58.8% had true uterine-preserving treatment.
We analyzed the survival of patients who underwent conization alone (n = 36) compared with trachelectomy (n = 89). Five-year DSS for the conization group was 90%, compared with 94.1% for the trachelectomy group (P = 0.43). However, 72.7% of patients undergoing conization received adjuvant RT, whereas only 27.3% undergoing trachelectomy received adjuvant RT. When analyzing only those patients who did not receive adjuvant RT, there was no significant difference in 5-year DSS (conization 100% vs trachelectomy 93.6%, P = 0.33). 
DISCUSSION
Uterine preservation has become an increasingly significant issue among young cancer patients, especially because many women now delay childbearing. For many female cancer survivors, the negative psychosocial impact due to loss of fertility persists years after diagnosis. 15, 16 The majority of cervical cancer patients aged younger than 45 are found to have stage I disease, which is associated with excellent survival. 17 Preserving both fertility and a sense of normalcy after oncologic treatment are critical for these women.
In the current study, UPS resulted in excellent DSS in patients with stage IB1 cervical cancer, similar to those who did not undergo UPS. This is likely one of the largest studies reported for this cohort and presents the longest follow-up. Long-term follow-up has also been reported in another study with a much smaller sample size of 40 patients undergoing radical trachelectomy versus 110 patients International
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* 2018 IGCS and ESGO undergoing non-UPS, which demonstrated no statistically significant difference in 5-year DSS between the 2 groups (92% vs 91%). 18 These findings are comparable to ours. We report a 5-year DSS of 92.9% versus 93.7% for UPS versus non-UPS, respectively; these are similar to the outcomes reported for radical hysterectomy with pelvic LN dissection in early-stage disease, for which the 5-year OS ranges from 73% to 98%.
19Y23 Recurrence and mortality rates of 2% to 5% and 1% to 2%, respectively, have also been reported in carefully selected patients with early-stage disease undergoing trachelectomy.
24Y27
Radical trachelectomy is considered the mainstay of UPS for stage IB1 cervical cancer. However, conization has emerged as a potential alternative to trachelectomy in select cases. 28 In the current study, we analyzed 36 stage IB1 patients who underwent conization. Our results demonstrated no significant difference in DSS between patients undergoing conization compared with trachelectomy, with 5-year DSS of 90% and 94%, respectively. In a recent meta-analysis of patients with stage IB1 cervical cancer, including 167 conization and 148 trachelectomies, the recurrence rate was 2% for conization and 2.3% for trachelectomy. 29 However, survival We noted an association between adenosquamous histology and worsened DSS. However, only 8 of 239 adenosquamous cases underwent UPS, making it impossible to draw any conclusion regarding UPS in the setting of this specific histology.
Tumor size is recognized as an important prognostic factor in cervical cancer. 30Y32 The UPS has typically been reserved for smaller tumors (2 cm or less in diameter).
11Y13
Tumors greater than 2 cm are associated with a higher rate of recurrence in general (3% for lesions 2 cm or less vs 17% for lesions 92 cm) 10 and worse OS. There are limited data regarding UPS in IB1 disease with tumors greater than 2 cm. In our analysis of tumors greater than 2 cm, there was no statistically significant difference in DSS between the UPS and non-UPS groups (82.4% vs 90.4%, respectively, P = 0.112). However, there is a distinct separation of the two survival curves (Fig. 1C) . This may reflect worse DSS in the UPS group that was not statistically detectable because of sample size, or there may truly be no significant difference in DSS. These results must therefore be interpreted with caution.
It is important to note that, among the patients with tumors greater than 2 cm who underwent UPS, 41.2% received adjuvant RT; thus, only 58.8% had true fertilitypreserving treatment (compared with 90.8% of patients with tumors 2 cm or less). Furthermore, regardless of the type of surgical approach, patients with larger tumors had significantly worse 5-year DSS (96.3% for tumor size 2 cm or less vs 90.2% for tumor size 92 cm).
The LN assessment is an important factor in triaging patients to appropriate postoperative management. In this study, 91% of all stage IB1 patients underwent LN examination, yet only 64% of those treated with UPS had LN assessment. The LN involvement is one of the most significant prognostic factors, and the risk of metastasis in stage IB1 cervical cancer is 15%. 33 It is imperative that patients undergo complete surgical staging, including LN evaluation either by lymphadenectomy or sentinel LN biopsy, especially if UPS is considered.
When counseling patients about fertility-preserving options, it is crucial to discuss reproductive outcomes. These tend to be slightly different depending on the type of procedure performed, but are generally quite promising. Unfortunately, the SEER database does not collect information on obstetrical outcomes for women with early-stage cervical cancer who undergo successful UPS. In the published literature, fertility rates (20%Y74%) and prematurity rates (5%Y57%) vary widely; however, spontaneous abortion rates (15%Y24%) are similar to those in the general public. Live birth rates are favorable, ranging from 67% to 78%.
29,34Y36
The current study has several limitations, including its retrospective nature, lack of central pathology review, lack of certain pathologic data such as depth of invasion, lymphovascular space invasion and margin status, and absence of data on reproductive outcomes and disease recurrence. The selection criteria for UPS or adjuvant RTwere not documented. Thus, there was likely a selection bias for patients who underwent UPS. Nevertheless, this study encompasses a large patient population, provides important information on long-term oncologic outcomes, and has robust external validity. It would be very difficult to perform a randomized controlled trial of cervical cancer patients wishing to preserve reproductive function because women desiring future fertility would probably be unwilling to risk randomization to the non-UPS arm. Large retrospective studies such as ours are, therefore, of high value. There are currently 3 prospective trials (SHAPE trial, GOG 278, and the LESER trial) recruiting to evaluate quality of life and oncologic outcomes in women with early-stage cervical cancer undergoing less versus more radical surgery. Although only 1 trial (GOG 278) offers a fertility-sparing option, these studies may present some important insights into the radicality necessary for the treatment of early-stage cervical carcinoma.
In conclusion, UPS does not seem to compromise DSS in properly selected young women with stage IB1 cervical cancer. The UPS in tumors greater than 2 cm should be performed with caution, and only in carefully selected patients, until additional studies clarify the role of uterine preservation in the setting of these larger tumors. Conization alone seems to be feasible and safe in properly selected patients with favorable risk factors. Young women with stage IB1 cervical cancer who desire fertility preservation should be extensively counseled, and LN assessment (which should be performed in all surgical patients) is mandatory in those being considered for UPS. Ongoing studies involving the use of neoadjuvant chemotherapy followed by conization or trachelectomy may offer women with early-stage disease and poor prognostic factors, including large tumor size, the option of uterine preservation without compromising oncologic outcomes.
